For patients with poor adherence to daily injections (e.g., elderly T2D patients with comorbidities and polypharmacy, or those reluctant to initiate insulin due to injection burden), insulin efsitora’s once-weekly dosing provides a more convenient alternative-addressing a major barrier to insulin initiation and potentially improving long-term treatment persistence (35, 36). The gene discussed is INS; the disease is type 2 diabetes mellitus.